Thorne
Provider of nutritional supplements, health diagnostics technology platforms, and medical education.
- Healthcare
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 2.8x EV/Revenue 33.5x EV/EBITDA | round | |
* | $680m Valuation: $680m 2.4x EV/Revenue 66.0x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 35 % | 34 % | 23 % | 26 % | 28 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (9 %) | 4 % | 8 % | 5 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (16 %) | (2 %) | 4 % | 7 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 3 % | 3 % | 3 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Thorne was founded in 1984 with a mission to revolutionize the nutritional supplement industry. The company was established by Al Czap and Paul Jacobson, who envisioned a brand that prioritized quality and scientific rigor in its product offerings. Over the years, Thorne has become a trusted name in the health and wellness sector, known for its commitment to purity and efficacy.
In September 2021, Thorne HealthTech made a significant leap by going public on the NASDAQ under the ticker THRN, with an initial stock price of $10.00. This move marked a new chapter in Thorne's journey, providing the company with the capital to expand its research and development capabilities and broaden its product line.
However, the most pivotal moment in Thorne's history came in October 2023, when L Catterton, a global consumer-focused private equity firm, completed its acquisition of Thorne HealthTech. The acquisition, valued at approximately $680 million, resulted in Thorne's delisting from the NASDAQ. This strategic move was aimed at leveraging L Catterton's resources and expertise to further Thorne's growth and innovation in the wellness industry.
Today, Thorne continues to lead in the health and wellness space, driven by its foundational principles of quality and scientific integrity. The company's journey from a small supplement manufacturer to a major player in the industry exemplifies its resilience and adaptability in a rapidly evolving market.
Tech stack
Investments by Thorne
Edit
